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Women bear a disproportionate burden of the HIV epidemic in
sub-Saharan Africa and account for about 60% of all adults living
with HIV in that region. Young women, including adolescent
girls, unable to negotiate mutual faithfulness and/or condom use
with their male partners are particularly vulnerable. In addition to
the high HIV burden, women in Africa also experience high rates
of other sexually transmitted infections and unwanted
pregnancies. The development of technologies that can
simultaneously meet these multiple sexual reproductive health
needs would therefore be extremely beneficial in the African
setting.
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HIV epidemic in Africa
Africa is the worst AIDS-affected region of the world, with
eastern and southern Africa generally more severely affected
than western and northern Africa (Figure 1). The HIV epi-
demic in Africa was identified in the early 1980s,1 but
probably originated several decades before this.2
While the emergence and magnitude of the HIV epi-
demic varies considerably between individual countries in
Africa, the HIV-1 epidemic is now well established within
the general population of sub-Saharan Africa where 5% of
all adults are estimated to be living with HIV.3 Substantial
progress has been made over the last decade in reducing
the number of new HIV infections among adults and chil-
dren and epidemiological trends indicate that most of the
HIV epidemics in Africa are either stabilising or declining.3
However, these encouraging trends mask the continued
spread of HIV in young women and sub-Saharan Africa
still accounts for about 70% (25 million) of the 35.3 mil-
lion people estimated to be infected with HIV globally in
2012.4 Countries like South Africa, Swaziland, Lesotho and
Malawi continue to experience unprecedented high HIV
prevalence and incidence rates.3
Access to anti-retroviral drugs to treat AIDS patients and
reduce vertical transmission of HIV has resulted in a 24%
decline in AIDS-related mortality since 2005 and almost
eliminated HIV infection in infants in some parts of the
world. Despite these successes, the majority (70%) of
AIDS-related deaths still occur in sub-Saharan Africa.3
Burden of HIV among young women
Women bear a disproportionate burden of the HIV epi-
demic in sub-Saharan Africa and account for approxi-
mately 60% of all infections in this region.5 HIV-infected
women between the ages of 15 and 24 years represent 76%
of the total cases in that age group.6 The rapid spread of
HIV among adolescent girls and young women in South
Africa has been described as explosive.7 National, annual,
anonymous seroprevalence surveys in pregnant women
using public sector healthcare facilities demonstrate that
HIV prevalence has increased from 0.8% in 1990 to 30.2%
in 2010.8 Although the national HIV prevalence appears to
be stabilising in South Africa, these data conceal geographi-
cal variations as well as age and gender differences in HIV
prevalence and incidence. HIV prevalence among pregnant
women, aged 15–49 years, is lowest in the Western Cape
Province (18.2%) and highest in the KwaZulu-Natal
Province, reaching 37.4% in 2011.8 Five sub-districts within
the KwaZulu-Natal Province have recorded HIV prevalence
that exceeds 40%.8 Annual cross-sectional surveys of
antenatal clinic attendees in one of these high-burden




sub-districts demonstrate a disturbing rise of HIV infection
among young women below the age of 20 years, increasing
from 16.6% in 2006 to 20.8% in 2008.9 A survey conducted
among high school students in this district shows that the
HIV prevalence in girls was six-fold higher than in boys.
An age-specific breakdown from this survey indicates that
by age 18, 7.1% of girls are infected with HIV and by age
25 this increases to 24%9 (Table 1).
These exceptionally high HIV prevalence rates are being
sustained by high HIV incidence rates among young
women. Several cohort studies have been conducted in
South Africa to measure HIV incidence.10–15 Results from
one of these cohort studies conducted between 2002 and
2005 in preparation for a microbicide trial showed that the
HIV incidence rate was 6.6 per 100 person-years. Factors
that were associated most strongly with HIV seroconver-
sion in this study included being below the age of 24 years,
being single, and having an incident sexually transmitted
infection (STI).14 Exceptionally high HIV incidence rates of
14.8 per 100 person-years (95% confidence interval [CI]
9.7–19.8) in women aged 18–35 years12 and 17.2 per 100
person-years (95% CI 2.1–62.2) in urban women below the
age of 20 years have been recorded in certain districts of
KwaZulu-Natal.16 More recent data from the Centre of
AIDS Programme of Research in South Africa (CAPRISA)
004 tenofovir gel trial, completed in 2010, show that the
HIV incidence rate remains high and was 9.1 per 100 per-
son-years among 18- to 40-year-old women in the placebo
gel arm.17
One of the key features of the HIV epidemic in sub-Sah-
aran Africa is the age–sex disparity in infection where
young women acquire HIV infection much earlier than
their male peers. This age–sex disparity was first docu-
mented in South Africa in the early 1990s18 and more
recent community-based surveys19 have demonstrated that
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Figure 1. Trends in (A) HIV prevalence and (B) number of infections in Africa between 1990 and 2010. The size of the red circles represents the
proportion of people infected. Source: Adapted from UNAIDS AIDSinfo www.unaids.org/en/





girls (95% CI) (n = 258)
HIV prevalence in
boys (95% CI) (n = 230)
12–14 1.6 (0.1–9.8) 5.0 (0.4–18.2)
15–16 2.6 (0.5–10.1) 1.1 (0.1–7.0)
17–18 7.1 (2.7–16.6) 0 (0.2–7.3)
19–25 24.0 (13.5–36.5) 0 (0.2–11.2)
Adapted from Kharsany et al. (2012).9
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the same gender disparities remain but the difference in
HIV prevalence between young women and men has been
exacerbated. Throughout eastern and southern Africa, the
prevalence of HIV in adolescent girls far exceeds that in
teenage boys, and South Africa has one of the largest abso-
lute ratios between girls and boys (Figure 2).
What makes young women more
vulnerable to HIV?
Several factors contribute to the increased vulnerability of
young women to acquiring HIV in sub-Saharan Africa.
Biologically, women appear to be more susceptible to
acquiring HIV than men. According to the US Centers for
Disease Control and Prevention, the risk of HIV infection is
1 per 2000 contacts for the male partner compared with
1 per 1000 contacts for the female partner in penile–vaginal
sex.20 Hence, on average, women are twice as likely to
become infected as men after a single sexual encounter
(Table 2). Although the biological mechanisms that make
women more vulnerable than men in acquiring HIV are not
fully understood, inflammation in the female genital tract is
emerging as an important risk factor for acquiring HIV.21 In
the CAPRISA 004 trial, women with genital inflammation
had an almost three-fold higher risk of HIV acquisition.21
The risk of acquiring HIV also increases with repeated
exposure, co-infection with ulcerative STIs,22–24 genital
immaturity, receptive anal sex, circumcision status of male
sexual partner,25 stage of HIV infection23,26 and the suscep-
tibility of the exposed individual.
While young women and girls are possibly more biologi-
cally prone to infection, this can only partially explain the
large gender differences in HIV prevalence. Discrimination
against women and girls in terms of access to education,
employment, health care, land and inheritance is common in
many low- and middle-income countries.27 Many women,
particularly those from impoverished backgrounds, form
relationships with men for financial and social security.28
Data from several African countries have shown that young
women who have sexual partners who are 5–10 years older
than them are at an increased risk for acquiring HIV.29–32
In addition to the intergenerational sexual coupling pat-
terns, early sexual debut and sexual violence also impact on
the vulnerability of young women in acquiring HIV infection
Figure 2. HIV prevalence (%) among people aged 15–24 years, by sex in selected African countries, 2008–11.5
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in sub-Saharan Africa. On average, young people begin hav-
ing sex in their teenage years and generally do not use con-
doms consistently. Studies from South Africa have shown
that the likelihood of early sexual debut increases when the
first sexual partners are older or if the sex is coerced.33 A
younger age of first sexual intercourse is associated with sub-
sequent sexual risk-taking behaviour, such as having multi-
ple partners,34 and an increased risk of acquiring STIs
including HIV infection.29,35 Teenage girls who acquire HIV
often drop out of school, which further perpetuates the vul-
nerability of young women as they transition to adulthood
due to the limited economic options available or accessible
to those who do not complete high school.
Women who have been subjected to intimate partner
violence have also been shown to be at an increased risk
for acquiring HIV36 and often adopt behaviours that place
them at an increased risk for acquiring HIV.5 Violence, the
fear of violence and stigma and discrimination also dis-
courage women from disclosing their HIV status.
Desperate economic circumstances also force some
women to engage in commercial sex for survival, which
places them at risk of contracting HIV and transmitting
the virus to others. According to the World Health
Organization, prevalence of HIV among sex workers in
sub-Saharan Africa is estimated to be 37%. The proportion
of HIV prevalence in the general female adult population
that is attributable to sex work has been estimated through
modelling to be 15% in 2011.37
High burden of STIs
Sexually transmitted infections are a major global public
health problem, resulting in acute illness, severe medical
complications, infertility, long-term disability and death in
millions of women each year.38 The burden of these STIs is
particularly severe in sub-Saharan Africa and especially in
young women. The World Health Organization estimates
that 110 million new cases of Chlamydia trachomatis, Neisse-
ria gonorrheae, Treponema pallidum (syphilis) and Tricho-
monas vaginalis occurred in the African region in 2005.38
The presence of STIs, particularly those that cause genital
ulceration or inflammation, has been shown to play an
important role in the transmission of HIV by increasing
the infectiousness of HIV-infected individuals and the sus-
ceptibility of HIV-uninfected individuals.39–42 Herpes sim-
plex virus type 2 (HSV-2) for example, which is a lifelong
and incurable infection that can cause recurrent and pain-
ful genital sores, has been shown to be associated with a
2.8-fold and 3.4-fold increased risk of HIV acquisition in
men and women, respectively, after adjustment for sexual
behaviour.43 An estimated 536 million (16.5%) sexually
active adults between the ages of 15 and 49 years were
infected with HSV-2 in 2003.44 The burden of HSV-2
infection is highest in sub-Saharan Africa where up to 80%
of sexually active women and up to 50% of sexually active
men are estimated to be infected.44–46
Human papillomaviruses (HPV), which include a highly
diverse group of obligate mucosal pathogens capable of infect-
ing and replicating in the genital epithelium, may also increase
the risk of acquiring HIV.47 A systematic review of the associa-
tion between HPV infection and HIV demonstrated that the
risk of HIV infection doubled in the presence of HPV.48 In
addition to the HIV risk, certain high-risk HPV types have
been shown to cause cervical cancer.49 An effective vaccine
against HPV has recently become available and could poten-
tially reduce the risk of both HIV and cervical cancer.
Given the strong association between the presence of
STIs and the increased risk of acquiring HIV, the treatment
of curable STIs would seem like a logical HIV prevention
tool. Unfortunately, only one trial, which was conducted in
Tanzania, has demonstrated a significant reduction in HIV
incidence rates following the treatment of STIs.50 Neverthe-
less, the significant sexual and reproductive health (SRH)
challenge posed by the high burden of curable STIs war-
rants the scaling up of known STI treatments, irrespective
of their impact on HIV.
High rates of unintended pregnancies
Besides a high STI burden, women in low- and
middle-income countries also experience high rates of
unintended pregnancies. According to the Guttmacher
Institute, of the 208 million pregnancies that occurred in
2008, about 86 million (41%) were unintended.51 About
half (41 million) of these unintended pregnancies were ter-
minated, often under unsafe conditions in non-health facil-
ity settings and especially in settings where termination of
Table 2. Estimated per-act probability of acquiring HIV from an
infected source, by exposure act.
Type of exposure Risk per
10 000 exposures
Sexual
Receptive anal intercourse 50
Receptive penile–vaginal intercourse 10
Insertive anal intercourse 6.5
Insertive penile–vaginal intercourse 5
Receptive oral intercourse Low
Insertive oral intercourse Low
Parenteral
Blood transfusion with infected blood 9000
Needle-sharing during injection drug use 67
Percutaneous (needle-stick) 30
Adapted from Centers for Diseases Control and Prevention20
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pregnancy is not legal.51 These nonspontaneous termina-
tions of pregnancy, the majority of which occur in low-
and middle-income countries, contribute to an estimated
70 000 maternal deaths and lead to serious complications
that require medical treatment in a further 8 million
women per year.52 About half of all maternal deaths each
year occur in young African women.53 Maternal deaths in
sub-Saharan Africa are being exacerbated by the HIV
epidemic, making the strengthening of HIV services for
pregnant women an urgent priority.54,55
Prevention of HIV, STIs and pregnancy
HIV prevention options for women
Despite the greater vulnerability of women, the options
available for reducing their risk of acquiring HIV infection
are limited.
Since the beginning of the epidemic the most widely
advocated HIV prevention methods have been the
‘ABCCC’ campaigns promoting Abstinence, Be faithful,
Condomise, Counselling and testing and later, Circumci-
sion. However, because of gender power imbalances,
women are often unable to successfully negotiate condom
use with their male partners, insist on mutual monogamy,
or convince their partners to have an HIV test.27,33,36,56
Furthermore, medical male circumcision primarily benefits
the male partner and does not seem to directly reduce the
HIV-acquisition risk in women.57
Since 2010, however, there have been a series of trials
demonstrating the efficacy of anti-retrovirals, as treatment58
or oral/topical prophylaxis,17,59–61 in reducing the risk of
sexually transmitted HIV infections. These new findings
have reinvigorated the HIV prevention field and the chal-
lenge now is to translate the clinical trial evidence into
practice and public health impact.
Treatment as prevention has been shown to reduce
HIV transmission in discordant couples by 96%.58 However,
for a woman to benefit from this prevention strategy she
would need to rely on her HIV-positive discordant male
partner to know his HIV status, to agree to be initiated on
anti-retroviral therapy even if he does not have AIDS and to
adhere to lifelong anti-retroviral therapy so that she can
benefit by being protected from acquiring HIV infection.
Given the reluctance of male partners to use the already
available prevention interventions, it is unlikely that they will
agree to early treatment initiation to benefit their partners.
In contrast, oral and topical anti-retrovirals, used as
pre-exposure prophylaxis, enable women to directly control
their own risk of acquiring HIV. Results from the Partners
PrEP60 and Botswana TDF261 studies have demonstrated
that oral pre-exposure prophylaxis (PrEP) is effective in
preventing HIV in women. However, two additional stud-
ies, the VOICE trial62 and the FemPrEP,63 showed no pro-
tective effect, primarily because of low levels of adherence
in those trials. These findings suggest that oral prophylaxis
is effective when used but may not be suitable in all popu-
lations and regions. Despite the potential impact of PrEP,
so far only the US Food and Drug Administration (FDA)
has officially approved Truvada (Gilead Sciences Inc.,
Foster City, CA, USA) as an HIV prevention option, and
guidelines have been developed for its use by the US
Centers for Disease Control and Prevention.64,65 Since
Truvada has not been approved by medicine regulators in
any other countries, country-specific individual patient
guidelines and programmatic public health guidelines on
the implementation of PrEP have not been developed.
Given that women bear a disproportionate burden of
HIV, prevention options that they can use and control
remain an important goal. The use of microbicides is one
of the most promising female-controlled HIV prevention
options in development. The candidate product in the
most advanced stage of testing is tenofovir gel, which was
shown in the CAPRISA 004 trial to reduce the risk of HIV
by 39% and of HSV-2 by 51% in women,17 making it a
multipurpose prevention technology (MPT). It was widely
anticipated that the VOICE (Vaginal and Oral Interven-
tions to Control the Epidemic) trial, which examined the
safety and effectiveness of 1% tenofovir gel and two oral
anti-retroviral agents (tenofovir and Truvada [a combina-
tion of tenofovir and emtricitabine] taken daily to reduce
the risk of HIV acquisition in women), would confirm
these results. Unfortunately, when the results were
announced in 2013 they showed that none of the interven-
tions provided protection against HIV. The lack of protec-
tive effect observed in the VOICE trial62 is largely a
consequence of suboptimal adherence; where only 23% of
women assigned to the tenofovir gel arm had had detect-
able drug levels.62 Another phase 3 trial, FACTS 001,66 is
currently underway to confirm the findings from the
CAPRISA 004 trial. If successful, the FACTS 001 trial could
provide the data needed for regulatory approval of tenofovir
gel and pave the way for the introduction of the first
microbicide.
Contraception
In contrast to limited prevention options for HIV, a multi-
tude of safe and effective options are already available to
prevent unwanted pregnancies. Despite the wide range of
available products, many unplanned pregnancies continue
to occur each year. Many of the undesired pregnancies
could be avoided if the unmet need for contraception, esti-
mated to be 25% in sub-Saharan Africa, was met.67 How-
ever, the inability to access contraception is not the only
reason for high rates of unintended pregnancies. Even in
the high-income countries like the USA, where access to
contraceptives is good, almost half of all pregnancies are
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unintended at the time of conception.68 Many individuals
and couples simply struggle with consistent, correct and
effective use of contraception.
Experience has shown that many men and women have
a negative attitude towards condoms, which represents a
significant barrier to their effective use. In the context of
HIV prevention, risk perception also impacts on willing-
ness to use condoms; individuals who do not perceive
themselves to be at risk appear less likely to wear con-
doms.69–71 Furthermore, in relationships where effective
forms of contraception like the oral pill or injectables are
being used, the use of condoms will be less likely. Like-
wise, in relationships where pregnancy is desired, or where
subordination of women limits their ability to negotiate
safer sex practices, condom use will be low.72 Female con-
doms also face additional challenges of higher cost, lower
availability and low acceptability, although new products
being developed and marketed strive to ameliorate some
of these challenges.
Multipurpose prevention technologies
Although STIs and unintended pregnancies are distinct sex-
ual and reproductive health problems, they are inextricably
linked. Women who are at risk for unintended pregnancies
are also those who are at risk of acquiring STIs, and vice
versa. Given the high rates of both STIs and unwanted preg-
nancies and the strong association between HIV and mater-
nal mortality in Africa, the development of technologies that
can simultaneously address these SRH needs would be extre-
mely beneficial.
The MPTs often referred to as ‘combination’ or ‘dual’
technologies, are innovative products currently under
development that are configured for at least two SRH pre-
vention indications. The products are intended to simulta-
neously prevent unintended pregnancy, and STIs, including
HIV, and/or reproductive tract infections.73 Multipurpose
prevention technologies in development include combina-
tions of devices and drugs, combinations of drugs or vac-
cines, and other novel approaches.74 Barrier devices like
male and female condoms and diaphragms are already
available and address multiple SRH needs. A multitude of
new MPT candidates are also in development and focus on
the development or improvement of physical barriers,
chemical barriers, and physical/chemical barrier combina-
tions. By targeting multiple SRH needs simultaneously,
MPTs potentially offer a cost-effective approach to address-
ing an important public health need, which could result in
social and economic benefits to women and their families
worldwide. Multipurpose prevention technologies also
include programmatic combinations of existing technolo-
gies that individually meet multiple SRH needs as part of
an integrated service.
Conclusion
Young women in the reproductive age group in sub-Saharan
Africa bear a disproportionate burden of HIV infection,
unwanted pregnancies and STIs, which are reversing gains
made in Millennium Development goals 4, 5 and 6. Keeping
young women in this region uninfected with HIV and free of
STIs and unwanted pregnancies will have enormous individ-
ual and population-level health and development benefits.
Yet, investment in technologies and programmes to address
their needs remains limited. There is an urgent need for
technologies including MPTs to meet the SRH needs of
women in sub-Saharan Africa. In addition to the individual
benefits of preventing HIV and or pregnancy or STIs, the
enhancement of HIV acquisition in the presence of STIs
makes prevention of both STIs and HIV particularly impor-
tant for the synergistic benefits of MPTs. However, as with
the development of the individual technologies, the develop-
ment of MPTs remains challenging.
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